In their letter, Reece and Hulse point to a lack of high quality comparative efficacy data for cannabis use in many conditions, in distinction to the efficacy data required for therapeutic goods already registered for these same indications. As outlined in our article,1 there are a number of “missing links” that need to be considered before Australia is confident that safe and effective cannabis can be available to people in need. Moreover, recent publications provide summaries of the evidence for and against its safety and efficacy.2,3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
